
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding Corp. is experiencing positive momentum, with a recent increase of approximately 4% in share value, reflecting heightened investor confidence and receptiveness among key opinion leaders regarding the company's innovative therapies. The encouraging feedback highlights the clinical relevance of improvements in functional measures, particularly in the treatment of spinal muscular atrophy (SMA), where patients have shown sustained gains rather than plateauing. Additionally, the company's operational preparedness and proactive educational efforts are setting the stage for successful product uptake, further enhancing the positive outlook for its pipeline in various therapeutic areas.
Bears say
Scholar Rock Holding Corp faces a negative outlook primarily due to the postponed commercial launch of its key product, apitegromab, now pushed back significantly to 2026 for the US and 2026 for the EU, which directly impacts projected peak sales estimates. The potential for regulatory approval delays and competitive risks from advancing therapies raises concerns about the company's market position and revenue generation capabilities, making investors wary. Furthermore, while clinical experts maintain confidence in apitegromab's safety and efficacy, the overall market sentiment is clouded by uncertainties surrounding regulatory hurdles and implications for growth, leading to a downward adjustment in projections.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares